Annual Current Liabilities
$139.10 M
+$26.61 M+23.65%
December 31, 2024
Summary
- As of February 21, 2025, HALO annual total current liabilities is $139.10 million, with the most recent change of +$26.61 million (+23.65%) on December 31, 2024.
- During the last 3 years, HALO annual current liabilities has risen by +$21.95 million (+18.74%).
- HALO annual current liabilities is now -66.99% below its all-time high of $421.38 million, reached on December 31, 2020.
Performance
HALO Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$139.10 M
+$30.29 M+27.83%
December 31, 2024
Summary
- As of February 21, 2025, HALO quarterly total current liabilities is $139.10 million, with the most recent change of +$30.29 million (+27.83%) on December 31, 2024.
- Over the past year, HALO quarterly current liabilities has increased by +$26.61 million (+23.65%).
- HALO quarterly current liabilities is now -66.99% below its all-time high of $421.38 million, reached on December 31, 2020.
Performance
HALO Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
HALO Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +23.6% | +23.6% |
| 3 y3 years | +18.7% | +20.8% |
| 5 y5 years | +62.4% | +20.8% |
HALO Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +23.6% | -30.3% | +51.3% |
| 5 y | 5-year | -67.0% | +62.4% | -67.0% | +433.5% |
| alltime | all time | -67.0% | >+9999.0% | -67.0% | >+9999.0% |
Halozyme Therapeutics Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $139.10 M(+23.7%) | $139.10 M(+27.8%) |
| Sep 2024 | - | $108.81 M(-18.4%) |
| Jun 2024 | - | $133.36 M(+1.3%) |
| Mar 2024 | - | $131.64 M(+17.0%) |
| Dec 2023 | $112.49 M(-14.0%) | $112.49 M(-2.3%) |
| Sep 2023 | - | $115.19 M(-1.0%) |
| Jun 2023 | - | $116.39 M(+26.6%) |
| Mar 2023 | - | $91.92 M(-29.7%) |
| Dec 2022 | $130.79 M(+11.6%) | $130.79 M(+19.6%) |
| Sep 2022 | - | $109.38 M(-45.2%) |
| Jun 2022 | - | $199.51 M(+78.6%) |
| Mar 2022 | - | $111.69 M(-4.7%) |
| Dec 2021 | $117.15 M(-72.2%) | $117.15 M(+3.5%) |
| Sep 2021 | - | $113.15 M(-1.0%) |
| Jun 2021 | - | $114.25 M(+6.4%) |
| Mar 2021 | - | $107.42 M(-74.5%) |
| Dec 2020 | $421.38 M(+392.1%) | $421.38 M(+1462.1%) |
| Sep 2020 | - | $26.98 M(+3.5%) |
| Jun 2020 | - | $26.07 M(-37.9%) |
| Mar 2020 | - | $42.00 M(-51.0%) |
| Dec 2019 | $85.64 M(-42.7%) | $85.64 M(-20.7%) |
| Sep 2019 | - | $108.04 M(-20.2%) |
| Jun 2019 | - | $135.42 M(-2.3%) |
| Mar 2019 | - | $138.66 M(-7.2%) |
| Dec 2018 | $149.36 M(+13.7%) | $149.36 M(+7.4%) |
| Sep 2018 | - | $139.12 M(+5.1%) |
| Jun 2018 | - | $132.43 M(+11.1%) |
| Mar 2018 | - | $119.22 M(-9.2%) |
| Dec 2017 | $131.33 M(+140.6%) | $131.33 M(+28.7%) |
| Sep 2017 | - | $102.05 M(+23.5%) |
| Jun 2017 | - | $82.61 M(+33.9%) |
| Mar 2017 | - | $61.71 M(+13.0%) |
| Dec 2016 | $54.59 M(-12.6%) | $54.59 M(+3.7%) |
| Sep 2016 | - | $52.66 M(+35.4%) |
| Jun 2016 | - | $38.88 M(-39.5%) |
| Mar 2016 | - | $64.22 M(+2.8%) |
| Dec 2015 | $62.46 M(+156.7%) | $62.46 M(+39.3%) |
| Sep 2015 | - | $44.85 M(+28.0%) |
| Jun 2015 | - | $35.04 M(+33.7%) |
| Mar 2015 | - | $26.21 M(+7.7%) |
| Dec 2014 | $24.33 M(-2.3%) | $24.33 M(-29.7%) |
| Sep 2014 | - | $34.59 M(+9.1%) |
| Jun 2014 | - | $31.72 M(-12.8%) |
| Mar 2014 | - | $36.36 M(+46.0%) |
| Dec 2013 | $24.90 M | $24.90 M(-37.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $39.62 M(+20.7%) |
| Jun 2013 | - | $32.83 M(+66.2%) |
| Mar 2013 | - | $19.75 M(+4.2%) |
| Dec 2012 | $18.95 M(+9.5%) | $18.95 M(-9.9%) |
| Sep 2012 | - | $21.04 M(+30.3%) |
| Jun 2012 | - | $16.15 M(-3.2%) |
| Mar 2012 | - | $16.68 M(-3.6%) |
| Dec 2011 | $17.30 M(+12.8%) | $17.30 M(+25.4%) |
| Sep 2011 | - | $13.79 M(-56.3%) |
| Jun 2011 | - | $31.54 M(+150.3%) |
| Mar 2011 | - | $12.60 M(-17.9%) |
| Dec 2010 | $15.34 M(+6.6%) | $15.34 M(+30.2%) |
| Sep 2010 | - | $11.78 M(+6.5%) |
| Jun 2010 | - | $11.06 M(-19.6%) |
| Mar 2010 | - | $13.76 M(-4.4%) |
| Dec 2009 | $14.40 M(+1.3%) | $14.40 M(-9.0%) |
| Sep 2009 | - | $15.81 M(+4.3%) |
| Jun 2009 | - | $15.17 M(+13.8%) |
| Mar 2009 | - | $13.33 M(-6.2%) |
| Dec 2008 | $14.22 M(+60.4%) | $14.22 M(+28.5%) |
| Sep 2008 | - | $11.06 M(+17.6%) |
| Jun 2008 | - | $9.41 M(-2.0%) |
| Mar 2008 | - | $9.60 M(+8.3%) |
| Dec 2007 | $8.86 M(+108.5%) | $8.86 M(+7.3%) |
| Sep 2007 | - | $8.26 M(+37.7%) |
| Jun 2007 | - | $6.00 M(+16.4%) |
| Mar 2007 | - | $5.16 M(+21.3%) |
| Dec 2006 | $4.25 M(+84.5%) | $4.25 M(+54.2%) |
| Sep 2006 | - | $2.76 M(+13.7%) |
| Jun 2006 | - | $2.43 M(-9.9%) |
| Mar 2006 | - | $2.69 M(+16.9%) |
| Dec 2005 | $2.30 M(+45.8%) | $2.30 M(+27.2%) |
| Sep 2005 | - | $1.81 M(+5.6%) |
| Jun 2005 | - | $1.72 M(-11.0%) |
| Mar 2005 | - | $1.93 M(+22.1%) |
| Dec 2004 | $1.58 M(>+9900.0%) | $1.58 M(-20.7%) |
| Sep 2004 | - | $1.99 M(+53.9%) |
| Jun 2004 | - | $1.29 M(+67.3%) |
| Mar 2004 | - | $773.20 K(>+9900.0%) |
| Sep 2003 | - | $4800.00(0.0%) |
| Jun 2003 | - | $4800.00(-66.7%) |
| Mar 2003 | - | $14.40 K(+213.0%) |
| Sep 2002 | - | $4600.00(+39.4%) |
| Jun 2002 | - | $3300.00(-35.3%) |
| Mar 2002 | - | $5100.00 |
| Dec 2001 | $3300.00 | - |
FAQ
- What is Halozyme Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual current liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly current liabilities year-on-year change?
What is Halozyme Therapeutics annual total current liabilities?
The current annual current liabilities of HALO is $139.10 M
What is the all time high annual current liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total current liabilities is $421.38 M
What is Halozyme Therapeutics annual current liabilities year-on-year change?
Over the past year, HALO annual total current liabilities has changed by +$26.61 M (+23.65%)
What is Halozyme Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of HALO is $139.10 M
What is the all time high quarterly current liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total current liabilities is $421.38 M
What is Halozyme Therapeutics quarterly current liabilities year-on-year change?
Over the past year, HALO quarterly total current liabilities has changed by +$26.61 M (+23.65%)